Shanghai Henlius Biotech
Clinical trials sponsored by Shanghai Henlius Biotech, explained in plain language.
-
New drug combo shows promise in tough lung cancer trial
Disease control CompletedThis phase 3 trial tested whether adding the experimental drug HLX10 to standard chemotherapy helps people with extensive-stage small cell lung cancer live longer. About 585 participants who had not received prior treatment were randomly assigned to get either HLX10 plus chemo or…
Phase: PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
New drug for lung scarring passes first safety check in healthy people
Knowledge-focused CompletedThis early-stage study tested a single dose of an experimental drug called HLX6018 in 66 healthy adults to see if it is safe and how the body processes it. The drug is being developed for idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. No treatment was given…
Phase: PHASE1 • Sponsor: Shanghai Henlius Biotech • Aim: Knowledge-focused
Last updated May 17, 2026 02:18 UTC